Published in J Clin Oncol on May 26, 2009
Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) | NCT00687102
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00
Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol (2010) 2.00
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat (2012) 1.66
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol (2010) 1.45
Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst (2013) 1.34
Clinically relevant measures of fit? A note of caution. Am J Epidemiol (2012) 1.34
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines. BMC Med (2013) 1.27
Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res (Phila) (2011) 1.19
Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study. Eplasty (2010) 1.14
Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet (2012) 1.13
Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med (2013) 1.11
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother (2011) 1.08
Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol (2010) 1.05
Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer (2010) 1.03
Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat (2011) 0.99
Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol (2012) 0.97
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol Oncol (2009) 0.97
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. J Clin Pharmacol (2011) 0.95
Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol (2015) 0.95
Net reclassification improvement: a link between statistics and clinical practice. Eur J Epidemiol (2013) 0.93
In their own words: treating very young BRCA1/2 mutation-positive women with care and caution. PLoS One (2014) 0.90
Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. PLoS One (2014) 0.88
Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res (2012) 0.87
Exemestane for breast cancer prevention: a critical shift? Cancer Discov (2012) 0.85
Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools. AMIA Annu Symp Proc (2015) 0.85
CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol (2011) 0.83
Retracted Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother (2011) 0.83
CYP2D6 testing to predict response to tamoxifen in women with breast cancer. Pharmacogenomic. PLoS Curr (2010) 0.83
Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care (2014) 0.83
The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors. J Drug Deliv (2013) 0.82
Birth weight, breast cancer and the potential mediating hormonal environment. PLoS One (2012) 0.82
Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention. Curr Breast Cancer Rep (2012) 0.82
Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw (2010) 0.81
Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast J (2015) 0.81
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol (2010) 0.80
Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study. Breast Cancer Res Treat (2013) 0.80
Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause (2013) 0.80
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med (2012) 0.80
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer (Dove Med Press) (2011) 0.80
Exemestane in the prevention setting. Ther Adv Med Oncol (2012) 0.79
An unusual BRCA mutation distribution in a high risk cancer genetics clinic. Fam Cancer (2013) 0.79
Breast cancer chemoprevention: progress and controversy. Surg Oncol Clin N Am (2010) 0.78
Developing a self-administered questionnaire as a guide to consultations with women treated for breast cancer. Int J Family Med (2011) 0.77
Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial. Br J Cancer (2011) 0.77
Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience (2015) 0.77
Estrogens and Male Lower Urinary Tract Dysfunction. Curr Urol Rep (2015) 0.76
Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. Breast Cancer Res Treat (2013) 0.76
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers (Basel) (2012) 0.76
Establishing a program for individuals at high risk for breast cancer. J Cancer (2013) 0.75
Computational study of estrogen receptor-alpha antagonist with three-dimensional quantitative structure-activity relationship, support vector regression, and linear regression methods. Int J Med Chem (2013) 0.75
Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation. PLoS One (2010) 0.75
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. Eur J Cancer Prev (2016) 0.75
Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study. BMC Musculoskelet Disord (2016) 0.75
Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention. Biomed Res Int (2015) 0.75
Just another negative DVT? BMJ Case Rep (2013) 0.75
Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory. Breast Cancer (Auckl) (2017) 0.75
The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton. PLoS One (2014) 0.75
A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population. BBA Clin (2014) 0.75
Genetics for the general internist. Am J Med (2011) 0.75
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer (2017) 0.75
Prognostic and predictive value of low estrogen receptor expression in breast cancer. Curr Oncol (2017) 0.75
Awareness and current knowledge of breast cancer. Biol Res (2017) 0.75
Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Judgment under Uncertainty: Heuristics and Biases. Science (1974) 34.89
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care (1994) 19.87
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (2008) 8.70
Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med (2001) 7.94
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol (2007) 7.45
Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med (1992) 6.68
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst (2001) 5.97
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
The framing effect of relative and absolute risk. J Gen Intern Med (1993) 4.87
Presenting risk information--a review of the effects of "framing" and other manipulations on patient outcomes. J Health Commun (2001) 4.54
Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst (2008) 4.52
Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer (1994) 4.37
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
The visual communication of risk. J Natl Cancer Inst Monogr (1999) 4.24
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet (1998) 3.83
Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making (2007) 3.74
Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ (1994) 3.61
Strategies to help patients understand risks. BMJ (2003) 3.55
Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst (1994) 3.45
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst (2007) 3.39
Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making (1995) 3.21
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (2003) 3.20
Numeracy skill and the communication, comprehension, and use of risk-benefit information. Health Aff (Millwood) (2007) 3.18
Supporting informed consumer health care decisions: data presentation approaches that facilitate the use of information in choice. Annu Rev Public Health (2001) 3.08
Risk charts: putting cancer in context. J Natl Cancer Inst (2002) 2.96
A systematic review on communicating with patients about evidence. J Eval Clin Pract (2006) 2.91
Frequency or probability? A qualitative study of risk communication formats used in health care. Med Decis Making (2001) 2.90
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc (2006) 2.73
The effects of information framing on the practices of physicians. J Gen Intern Med (1999) 2.52
Strategies for reporting health plan performance information to consumers: evidence from controlled studies. Health Serv Res (2002) 2.52
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst (2003) 2.49
Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst (2007) 2.36
Communicating the uncertainty of harms and benefits of medical interventions. Med Decis Making (2007) 2.34
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24
Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol (1999) 2.23
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Perils, pitfalls, and possibilities in talking about medical risk. JAMA (1999) 2.08
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol (2008) 2.01
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation (2005) 2.01
Women's perceptions of breast cancer risk: how you ask matters. Med Decis Making (1999) 2.00
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Med Inform Decis Mak (2001) 1.88
A new scale for assessing perceptions of chance: a validation study. Med Decis Making (2000) 1.88
Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med (2001) 1.87
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res (2007) 1.79
Personalised risk communication for informed decision making about taking screening tests. Cochrane Database Syst Rev (2006) 1.73
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry (2005) 1.62
Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab (2006) 1.60
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol (1999) 1.52
Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med (2003) 1.51
The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res (2002) 1.51
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology (2004) 1.48
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol (2006) 1.47
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol (2002) 1.42
Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat (2000) 1.40
Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev (2006) 1.39
Interventions to improve risk communication in clinical genetics: systematic review. Patient Educ Couns (2008) 1.31
Prescribing propensity: influence of life-expectancy gains and drug costs. J Gen Intern Med (1994) 1.24
Communicating breast cancer risks to women using different formats. Cancer Epidemiol Biomarkers Prev (2001) 1.22
Aromatase inhibitors for breast cancer prevention. J Clin Oncol (2005) 1.19
Barriers to minority participation in breast carcinoma prevention trials. Cancer (2005) 1.18
Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology (2004) 1.15
Patients' interpretations of verbal expressions of probability: implications for securing informed consent to medical interventions. Behav Sci Law (1994) 1.10
Breast cancer risk assessment models: applicability to African-American women. Cancer (2003) 1.09
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res (2005) 1.06
Participation of Asian-American women in cancer chemoprevention research: physician perspectives. Cancer (2005) 1.05
9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res (2000) 1.04
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst (2006) 1.03
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol (2003) 0.98
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol (2002) 0.96
Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology (1999) 0.96
Patients' and physicians' interpretations of graphic data displays. Med Decis Making (1993) 0.96
The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women Health (2000) 0.93
Communicating risk reductions. Researchers should present results with both relative and absolute risks. BMJ (1999) 0.92
Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol (2006) 0.91
Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol (2006) 0.91
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med (2008) 0.89
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol (2007) 0.89
Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer (2000) 0.86
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet (2010) 15.50
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Lung cancer. N Engl J Med (2008) 13.49
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol (2006) 11.07
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2011) 9.75
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2014) 8.74
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (2008) 8.70
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA (2004) 8.12
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol (2010) 7.29
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2009) 6.66
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol (2003) 6.66
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet (2003) 6.15
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol (2003) 5.69
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 4.94
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (2010) 4.73
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol (2011) 4.64
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol (2002) 4.55
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc (2003) 4.44
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
The prevention of depressive symptoms in children and adolescents: A meta-analytic review. J Consult Clin Psychol (2006) 4.15
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 3.92
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85